These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26890411)

  • 21. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone regeneration with active angiogenesis by basic fibroblast growth factor gene transfected mesenchymal stem cells seeded on porous beta-TCP ceramic scaffolds.
    Guo X; Zheng Q; Kulbatski I; Yuan Q; Yang S; Shao Z; Wang H; Xiao B; Pan Z; Tang S
    Biomed Mater; 2006 Sep; 1(3):93-9. PubMed ID: 18458388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the delivery of small interfering RNAs into mammalian cells.
    Sioud M
    Expert Opin Drug Deliv; 2005 Jul; 2(4):639-51. PubMed ID: 16296791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of nanocarriers for the delivery of small interfering RNA.
    Kesharwani P; Gajbhiye V; Jain NK
    Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breaking down the barriers: siRNA delivery and endosome escape.
    Dominska M; Dykxhoorn DM
    J Cell Sci; 2010 Apr; 123(Pt 8):1183-9. PubMed ID: 20356929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?
    Guo J; Bourre L; Soden DM; O'Sullivan GC; O'Driscoll C
    Biotechnol Adv; 2011; 29(4):402-17. PubMed ID: 21435387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
    Dykxhoorn DM; Lieberman J
    Annu Rev Biomed Eng; 2006; 8():377-402. PubMed ID: 16834561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
    Kapoor M; Burgess DJ; Patil SD
    Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review: gene- and stem cell-based therapeutics for bone regeneration and repair.
    Kimelman N; Pelled G; Helm GA; Huard J; Schwarz EM; Gazit D
    Tissue Eng; 2007 Jun; 13(6):1135-50. PubMed ID: 17516852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide application of RNAi to the discovery of potential drug targets.
    Ito M; Kawano K; Miyagishi M; Taira K
    FEBS Lett; 2005 Oct; 579(26):5988-95. PubMed ID: 16153642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology for in vivo targeted siRNA delivery.
    Dahlman JE; Kauffman KJ; Langer R; Anderson DG
    Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in RNAi-based antiviral therapeutics.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():67-75. PubMed ID: 21431679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
    Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
    J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-viral gene therapy for bone tissue engineering.
    Wegman F; Oner FC; Dhert WJ; Alblas J
    Biotechnol Genet Eng Rev; 2013; 29():206-20. PubMed ID: 24568281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective siRNA delivery to inflamed primary vascular endothelial cells by anti-E-selectin and anti-VCAM-1 PEGylated SAINT-based lipoplexes.
    Leus NG; Talman EG; Ramana P; Kowalski PS; Woudenberg-Vrenken TE; Ruiters MH; Molema G; Kamps JA
    Int J Pharm; 2014 Jan; 459(1-2):40-50. PubMed ID: 24239833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
    Martirosyan A; Olesen MJ; Howard KA
    Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.